180 related articles for article (PubMed ID: 30275211)
1. Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.
Sugiyama K; Narita Y; Mitani S; Honda K; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Ando M; Tajika M; Muro K
Anticancer Res; 2018 Oct; 38(10):5859-5866. PubMed ID: 30275211
[TBL] [Abstract][Full Text] [Related]
2. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics Associated with Long-term Survival in Metastatic Gastric Cancer after Systemic Chemotherapy.
Kadowaki S; Komori A; Takahari D; Ura T; Ito S; Tajika M; Niwa Y; Oze I; Muro K
Asian Pac J Cancer Prev; 2015; 16(13):5433-8. PubMed ID: 26225690
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.
Ma LX; Taylor K; Espin-Garcia O; Anconina R; Suzuki C; Allen MJ; Honorio M; Bach Y; Allison F; Chen EX; Brar S; Swallow CJ; Yeung J; Darling GE; Wong R; Kalimuthu SN; Jang RW; Veit-Haibach P; Elimova E
Cancer Med; 2021 Jan; 10(1):199-207. PubMed ID: 33295697
[TBL] [Abstract][Full Text] [Related]
5. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer.
Lee JS; Kim YS; Kim EY; Jin W
PLoS One; 2018; 13(8):e0202700. PubMed ID: 30125312
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
Li QQ; Lu ZH; Yang L; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li J; Li Y; Shen L
Asian Pac J Cancer Prev; 2014; 15(2):945-50. PubMed ID: 24568523
[TBL] [Abstract][Full Text] [Related]
8. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).
Sasaki S; Oki E; Saeki H; Shimose T; Sakamoto S; Hu Q; Kudo K; Tsuda Y; Nakashima Y; Ando K; Akagi Y; Kakeji Y; Baba H; Maehara Y
Int J Clin Oncol; 2019 Oct; 24(10):1204-1213. PubMed ID: 31062115
[TBL] [Abstract][Full Text] [Related]
9. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
Li J; Qin S; Xu J; Guo W; Xiong J; Bai Y; Sun G; Yang Y; Wang L; Xu N; Cheng Y; Wang Z; Zheng L; Tao M; Zhu X; Ji D; Liu X; Yu H
J Clin Oncol; 2013 Sep; 31(26):3219-25. PubMed ID: 23918952
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and prognostic factors of metastatic gastric carcinoma patients who experience gastrointestinal perforation during palliative chemotherapy.
Kang MH; Kim SN; Kim NK; Park YI; Kim YW; Ryu KW; Lee JH; Lee JS; Park SR
Ann Surg Oncol; 2010 Dec; 17(12):3163-72. PubMed ID: 20585878
[TBL] [Abstract][Full Text] [Related]
11. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
12. Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial.
Park HS; Kim HS; Beom SH; Rha SY; Chung HC; Kim JH; Chun YJ; Lee SW; Choe EA; Heo SJ; Noh SH; Hyung WJ; Cheong JH; Kim HI; Son T; Lim JS; Baek SE; Jung M
Ann Surg Oncol; 2018 Oct; 25(11):3222-3230. PubMed ID: 30051367
[TBL] [Abstract][Full Text] [Related]
13. Chemoresponse after non-curative gastrectomy for M1 gastric cancer.
Shin HB; Lee SH; Son YG; Ryu SW; Sohn SS
World J Surg Oncol; 2015 Jan; 13():13. PubMed ID: 25634223
[TBL] [Abstract][Full Text] [Related]
14. The impact of neoadjuvant chemotherapy on skeletal muscle depletion and preoperative sarcopenia in patients with resectable colorectal liver metastases.
Eriksson S; Nilsson JH; Strandberg Holka P; Eberhard J; Keussen I; Sturesson C
HPB (Oxford); 2017 Apr; 19(4):331-337. PubMed ID: 28089364
[TBL] [Abstract][Full Text] [Related]
15. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
[TBL] [Abstract][Full Text] [Related]
16. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features and treatment outcomes of metastatic or locally unresectable small bowel adenocarcinoma.
Li X; Ying H; Cheng Y; Zhao L; Zhao S; Bai C; Zhou J
J BUON; 2019; 24(6):2539-2545. PubMed ID: 31983130
[TBL] [Abstract][Full Text] [Related]
18. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Machida N; Yoshino T; Boku N; Hironaka S; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Asaka M
Jpn J Clin Oncol; 2008 Oct; 38(10):689-94. PubMed ID: 18845522
[TBL] [Abstract][Full Text] [Related]
19. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
[TBL] [Abstract][Full Text] [Related]
20. Optimal Cutoff Values of Skeletal Muscle Index to Define Sarcopenia for Prediction of Survival in Patients with Advanced Gastric Cancer.
Nishigori T; Tsunoda S; Obama K; Hisamori S; Hashimoto K; Itatani Y; Okada K; Sakai Y
Ann Surg Oncol; 2018 Nov; 25(12):3596-3603. PubMed ID: 30167910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
